Page 27 - Pacemaker News Today

Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers.

A study in Nature Communications delves into how the liver's circadian clock responds to meal timing, impacting fat metabolism and other bodily processes. The research underscores the intricate network that contributes to liver's diurnal rhythms, regulated by protein phosphorylation and nutrient availability.

A private heart clinic in Hastings offers procedures without the need to leave region.

From breast implants to prosthetic knees, implants can trigger a foreign body response that results in your body rejecting them. Suppressing an immune cell gene could reduce this risk.

A multidisciplinary team of clinicians, engineers, and neuroscientists has identified a unique biomarker in the brain that indicates recovery from treatment-resistant depression, utilizing deep brain stimulation (DBS) and artificial intelligence. The discovery, which allows for real-time monitoring and tailoring of treatment, could revolutionize the approach to managing severe forms of depression.

Starring 2023 Tony Award winner Alex Newell, the first-ever non-binary actor to win a Tony, multi-Grammy Award winner Philip Lawrence, and executive produced by ‘Nimona’s ND Stevenson, the 3DCG film, about a grandfather’s hopeful acceptance of his trans grandson, begins a week-long Oscar-qualifying run September 15 at the Cinelounge Sunset in Hollywood. 

In the last 12 months, two orthobiologics companies have expanded their focus and rebranded.

Review comprehensively explores how the circadian rhythm impacts sports performance, hormonal regulation, and immune system function in athletes. The study emphasizes the optimal times of day for athletic performance and underlines the role of circadian rhythm in hormonal balance and immune responses.

Researchers examined whether flash therapy, given during sleep, changed the sleep architecture to shift the human circadian clock.

Results of the DANPACE II randomized trial refute the theory that slower pacing can reduce the risk of atrial fibrillation in patients with sinus node dysfunction.